儿童肥胖中的脂肪性肝病与青年起病2型糖尿病风险增加
基于瑞典儿童肥胖治疗登记(BORIS,1999-2020)的队列研究,纳入10,346名超重或肥胖儿童及59,336名匹配对照,评估儿童肥胖中代谢功能障碍相关脂肪性肝病(MASLD)与青年起病2型糖尿病的关联。MASLD与2型糖尿病风险相关(HR 2.71),与中间高血糖联合时风险协同增至HR 9.04,肥胖治疗最佳应答降低风险(HR 0.23)。
要点
- 儿童肥胖合并MASLD者30岁时2型糖尿病累积发病率为22.7%,单纯肥胖为9.9%,对照为0.7%。
- MASLD与2型糖尿病风险相关(HR 2.71,95%CI 2.14-3.43),独立于年龄、性别、肥胖程度、中间高血糖及父母2型糖尿病。
- MASLD与中间高血糖联合效应使2型糖尿病风险增至HR 9.04(95%CI 6.38-12.79)。
核心结论
- 儿童肥胖中由转氨酶或诊断代码定义的MASLD与青年起病2型糖尿病风险增加相关。
- MASLD与中间高血糖协同作用,大幅增加2型糖尿病风险。
- 肥胖治疗最佳应答降低2型糖尿病风险,尽管存在MASLD。
研究设计与样本
- 队列研究,使用瑞典儿童肥胖治疗登记(BORIS,1999-2020)与国家登记链接。
- 纳入10,346名超重或肥胖儿童和59,336名匹配对照个体。
- MASLD分别由转氨酶和诊断代码定义。
- 2型糖尿病从国家登记确认。
主要发现
- 肥胖队列中2型糖尿病诊断中位年龄为16.9岁(Q1,Q3:14.7,21.4),中位随访8.1年(Q1,Q3:5.1,11.7)。
- 30岁时2型糖尿病累积发病率:肥胖合并MASLD为22.7%,单纯肥胖为9.9%,对照个体为0.7%。
- MASLD与2型糖尿病风险相关(HR 2.71,95%CI 2.14-3.43),独立于年龄、性别、肥胖程度、中间高血糖和父母2型糖尿病。
- MASLD与中间高血糖联合效应增加2型糖尿病风险(HR 9.04,95%CI 6.38-12.79)。
- 肥胖治疗最佳应答降低风险(HR 0.23,95%CI 0.09-0.57)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess 1) the association between metabolic dysfunction-associated steatotic liver disease (MASLD) in pediatric obesity and youth-onset type 2 diabetes, 2) the joint effect of MASLD and intermediate hyperglycemia on type 2 diabetes risk, and 3) the effect of obesity treatment on type 2 diabetes risk. RESEARCH DESIGN AND METHODS: A cohort study using the Swedish Childhood Obesity Treatment Register (Barnobesitas Registret i Sverige [BORIS]) (1999-2020) linked with national registers was conducted. We included 10,346 children with overweight or obesity and 59,336 matched control individuals. MASLD was defined by transaminases and diagnosis code, separately. Type 2 diabetes was ascertained from national registers. RESULTS: In the obesity cohort, median age at type 2 diabetes diagnosis was 16.9 (quartile 1 [Q1], quartile 3 [Q3]: 14.7, 21.4) years, median follow-up was 8.1 (Q1, Q3: 5.1, 11.7) years. Cumulative incidence of type 2 diabetes at age 30 was 22.7% (obesity and MASLD), 9.9% (obesity alone), and 0.7% (control individuals). MASLD was associated with risk for type 2 diabetes (hazard ratio [HR] 2.71 [95% CI 2.14-3.43]), independently of age, sex, degree of obesity, intermediate hyperglycemia, and parental type 2 diabetes. Joint effect of MASLD and intermediate hyperglycemia increased type 2 diabetes risk (HR 9.04 [6.38-12.79]). Optimal response in obesity treatment reduced the risk (HR 0.23 [0.09-0.57]). CONCLUSIONS: MASLD, defined by transaminases or diagnosis code, in pediatric obesity is associated with increased risk for youth-onset type 2 diabetes. MASLD interacts synergistically with intermediate hyperglycemia to dramatically increase the risk. Optimal response in obesity treatment reduces type 2 diabetes risk, despite MASLD.
引用
- Putri RR, Casswall T, Danielsson P, et al. Steatotic Liver Disease in Pediatric Obesity and Increased Risk for Youth-Onset Type 2 Diabetes. Diabetes Care. 2024. PMID: 39373987. doi:10.2337/dc24-1236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。